Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytomegalovirus Retinitis Retreatment Trial
NCT00000134Phase 3Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Dec 1992
- Primary completion
- Mar 1995
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised trial of foscarnet sodium and ganciclovir in cytomegalovirus retinitis (3 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoint: Morbidity at 12 months. Started Dec 1992; status: completed.
02
Drugs
foscarnet sodiumganciclovir
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00000134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000134.